Clinical Trials Sponsored by Eli Lilly and Company

Total 2624 results

Eli Lilly and Company

Completed

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Metastatic Breast Cancer

United States
Eli Lilly and Company

Completed

A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes (IMAGINE 6)

Diabetes Mellitus, Type 2

United States, Canada, Germany, Korea, Republic of, Hungary, Spain, Puerto Rico, Poland, Mexico, Argentina, Czechia
Eli Lilly and Company

Completed

A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor

Major Depressive Disorder

United Kingdom, United States, Belgium, Austria, Australia, Germany, Sweden
Eli Lilly and Company

Completed

A Study in Older Participants Who Have Fallen and Have Muscle Weakness

Muscle Weakness

France, United States, Argentina, Australia, Germany, Sweden
Eli Lilly and Company

Completed

A Rheumatoid Arthritis Study in Participants (FLEX O)

Rheumatoid Arthritis

Argentina, India, United States, Hungary, Bulgaria, Mexico, Ukraine, Colombia, Taiwan, Poland, Japan, Korea, Republic of, New Zealand, Romania, South Africa, Australia, Croatia, Lithuania, Malaysia, Russian Federation, Slovakia, Sri...
Eli Lilly and Company

Completed

A Study for Patients With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States, Israel
Eli Lilly and Company

Completed

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Head and Neck Cancer

United States
Eli Lilly and Company

Completed

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

Major Depressive Disorder

United States, South Africa, Poland, Ukraine, Japan, Russian Federation, Latvia
Eli Lilly and Company

Completed

A Study of LY3009104(Baricitinib) for Healthy Subjects

Healthy Volunteer

United States
Eli Lilly and Company

Completed

A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants

Healthy

United Kingdom
Eli Lilly and Company

Completed

A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)

Type1 Diabetes Mellitus

United States
Eli Lilly and Company

Completed

A Study of Baricitinib (LY3009104) in Healthy Chinese Participants

Healthy

China
Eli Lilly and Company

Completed

Treatment for Aggression and Agitation in Patients With Alzheimer's Disease

Alzheimer's Disease

United States
Eli Lilly and Company

Completed

A Study of LY2775240 in Healthy Participants

Healthy

Singapore
Eli Lilly and Company

Withdrawn

A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps

Diabetes Mellitus, Type 1
Eli Lilly and Company

Completed

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)

Erectile Dysfunction | Benign Prostate Hyperplasia

China
Eli Lilly and Company

Completed

Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Subjects

Healthy Volunteers

United States
Eli Lilly and Company

Completed

A Study of Baricitinib and Probenecid in Healthy Participants

Healthy Volunteers

United Kingdom
Eli Lilly and Company

Completed

A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants

Healthy Volunteers

United Kingdom
Eli Lilly and Company

Completed

A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants

Healthy Volunteers

United Kingdom
Eli Lilly and Company

Completed

A Study of Baricitinib and Omeprazole in Healthy Participants

Healthy Volunteers

United Kingdom
Eli Lilly and Company

Completed

Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors

Metastasis | Malignancy

Japan
Eli Lilly and Company

Completed

A Study of Olaratumab in Soft Tissue Sarcoma

Sarcoma, Soft Tissue

United States
Eli Lilly and Company

Completed

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloproliferative Neoplasms of

United States
Eli Lilly and Company

Completed

Safety Study of LY3041658 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY2875358 in Participants With Advanced Cancer

Advanced Cancer

United States
Eli Lilly and Company

Completed

Study of LY3039478 in Healthy Participants

Healthy

United Kingdom
Eli Lilly and Company

Completed

A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study of LY3200327 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Completed

A Study in Participants With Advanced Solid Tumors

Solid Tumor

China
Eli Lilly and Company

Completed

A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors

Solid Tumors

United States
Eli Lilly and Company

Completed

Study of Galunisertib in Healthy Participants

Healthy

United Kingdom
Eli Lilly and Company

Completed

A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer

Non-small Cell Lung Cancer

Spain, France, United States, Taiwan, Canada, Netherlands, Mexico
Eli Lilly and Company

Completed

A Study in Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
Eli Lilly and Company

Completed

A Phase 1 Study in Participants With Advanced Cancer

Carcinoma, Non-Small-Cell Lung | Advanced Cancer | Anal Squamous Cell Carcinoma | Squamous Cell Carcinoma | Carcinoma, Squamous Cell of Head and Neck | Lung Squamous Cell Carcinoma Stage IV

United States
Eli Lilly and Company

Completed

A Study of LY2624803 in Japanese Participants With Transient Insomnia

Sleep Initiation and Maintenance Disorders

Japan
Eli Lilly and Company

Completed

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States
Eli Lilly and Company

Completed

Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors

Advanced Cancer

Puerto Rico, United States
Eli Lilly and Company

Completed

Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

Carcinoma | Lung Neoplasms | Non-Small-Cell Lung Carcinoma | Cancer of the Lung

United States, Canada, Puerto Rico
Eli Lilly and Company

Completed

A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Eli Lilly and Company

Completed

A Study of [¹⁴C]-LY3023414 in Healthy Participants

Healthy

United States
Eli Lilly and Company

Withdrawn

A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel

Carcinoma, Non-Small-Cell Lung | Lung Neoplasms

United States
Eli Lilly and Company

Completed

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer

Metastatic Colorectal Cancer

Spain, United States, Canada
Eli Lilly and Company

Completed

A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

United States
Eli Lilly and Company

Completed

Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
Eli Lilly and Company

Completed

A Study of LY2189265 in Japanese Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Japan
Eli Lilly and Company

Completed

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico
Eli Lilly and Company

Completed

Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

France, Germany, Spain
Eli Lilly and Company

Completed

Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis

Inflammatory Arthritis

Bulgaria, Georgia, Moldova, Republic of, Romania
Eli Lilly and Company

Completed

A Study of LY2875358 in Japanese Participants With Advanced Cancer

Lymphoma | Carcinoma, Non-Small-Cell Lung | Solid Tumors

Japan

Clinical Trials Sponsored by Eli Lilly and Company

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations